AlphAIalphai — Financial news for AI agents
Stock TitanAPR 293 min read$KNSA

Kiniksa (KNSA) director Quart exercises options, sells 13,099 shares under 10b5-1 plan

Kiniksa Pharmaceuticals International, plc director Barry D. Quart exercised options to acquire 13,099 Class A Ordinary Shares at $14.33 per share and subsequently sold them at a weighted average price of $50.10. This transaction was conducted under a pre-arranged Rule 10b5-1 plan, indicating a pre-planned liquidity event. Following these actions, Quart directly holds 12,546 shares and retains 13,237 fully vested share options.

Original reporting
Stock Titan
Published Apr 29, 2026, 9:08 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 30, 2026, 7:00 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$KNSA
Bullish
medium confidence
Mentioned
$KNSA
alphai data visualization · based on Stock Titan
Decision brief

The 30-second read

$KNSABullishLow
01

Why it matters

The insider's planned sale suggests confidence but also a potential liquidity event; market reaction may vary.

02

Market read

Limited to company-specific insider activity; broader market implications are minimal.

03

What to watch

Market conditions and broader biotech sector trends could overshadow insider activity signals.

Timing: short-term

Background

KNSA is a biotech company with recent positive developments and insider activity indicating confidence.

Company-level read

Ticker impact

$KNSABullishMedium confidence
Context

The insider trading activity indicates a liquidity event by a company director, which may influence investor perception.

Expected impact

Moderate upward pressure on stock price in the short term, contingent on overall market conditions.

Evidence & confidence

The insider's sale under a 10b5-1 plan suggests planned liquidity rather than opportunistic selling, which is generally viewed neutrally or positively by the market.

Market effects

Sector

Potential positive sentiment in the life sciences sector due to insider confidence.

Regional

Minimal regional impact expected.

Global

Limited global relevance; specific to company insider activity.

Counterpoint

What could challenge this read

The insider sale might be a sign of overconfidence or upcoming dilution; caution is advised.

Key entities

  • Company
    Kiniksa Pharmaceuticals International, plc

    Biotech firm specializing in immune-mediated diseases.

  • Director
    Barry D. Quart

    Board member exercising options and selling shares.

Read at source← All news

Related articles

JUL 29
$TRIBMed

Top Biotech Gainers: KNSA Soars On Q2 Results, TRIB, OPK On Watch, MPLT On The Mend?

Biotech gainers included Trinity Biotech (TRIB), which rose 36% after Q2 results and a one-for-thirty reverse ADS split to regain Nasdaq bid compliance. OPKO Health (OPK) gained 33% on Q2 revenue of $163.5M and softer Q3/full-year guidance. Kiniksa (KNSA) jumped 25% after raising 2026 net product revenue outlook to $980M-$995M. MapLight (MPLT) rebounded 24% after mixed Phase 2 schizophrenia data. ProMIS (PMN) rose 24% on interim Alzheimer’s data; Prelude (PRLD) rose 19% without specific news.

rttnews.com7 min
JUL 28
$KNSAHighAI 9/10

Kiniksa Pharmaceuticals Shares Surge 21% on Strong ARCALYST Sales and Raised 2026 Guidance

Kiniksa Pharmaceuticals International plc shares rose about 21% on Nasdaq after its Q2 results for ARCALYST (rilonacept) beat expectations and it raised 2026 guidance. Net product revenue was $243.6M, about 55% higher year over year. 2026 guidance increased to $980M-$995M from $930M-$945M. Kiniksa also reported Q2 net income of $25.4M and $525.9M cash, and is enrolling PASTORALE for KPL-387.

ibtimes.com.au7 min
JUL 28
$KNSAMed

Kiniksa Pharmaceuticals International, plc (KNSA): Results of Operations and Financial Condition

Kiniksa Pharmaceuticals International, plc (KNSA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 knsa-20260728xex99d1.htm EX-99.1 Exhibit 99.1 ​ ​ ​ ​ Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution – ARCALYST ® (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth –

SEC EDGAR 8-K4 min
AUG 8
$SUNEMedAI 8/10

Pentagon to invest $400m in Australian rare earth mine

Sunrise Energy Metals said the US Pentagon will provide a conditional $400 million loan commitment to develop Syerston, a proposed scandium mine in Fifield, NSW. The project targets Western supply of scandium used in defence and other sectors amid China’s export restrictions. Sunrise also said it has a deal with Lockheed Martin for 25% of output for five years.

bssnews.net4 min
AUG 8
$WTRGMed

Trump administration to invest $3 billion in minerals projects to boost US defence supply chains

President Trump said the US will invest $3 billion in critical minerals and battery projects to expand domestic supply chains for national security. He announced Defence Department Office of Strategic Capital conditional loans totaling $1.4B to Sila Nanotechnologies, $400M to Sunrise Energy Metals, and $150M to Niron Magnetics, plus $58M Export-Import Bank loans. The plan also includes $100M in mining-school grants and $80M for three schools.

tribune.com.pk6 min